Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 2661-2667

  Louie, Arnold ^a   Deziel, Mark R ^a   Liu, Weiguo ^a   Drusano, George L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; BIOLOGICAL WARFARE; CLINICAL STUDY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; IN VITRO STUDY; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PLAGUE; PRIORITY JOURNAL; THIGH; YERSINIA PESTIS;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; HUMANS; IMMUNOCOMPETENCE; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; NEUTROPENIA; OFLOXACIN; PLAGUE; SELECTION (GENETICS); STREPTOMYCIN; THIGH; TREATMENT OUTCOME; YERSINIA PESTIS;

EID: 34547631104     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00073-07     Document Type: Article

References (41)

1. Alibek, K., and S. Handelman. 1999. Biohazard. Random House, New York, NY.
2. Appel, G. B. 1990. Aminoglycoside nephrotoxicity. Am. J. Med. 88(Suppl. C):16S-20S.
3. Bacot, A. W., and C. J. Martin. 1914. Observations on the mechanism of the transmission of plague by fleas. J. Hyg. 13(Plague Suppl. 3):423-439.
4. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
5. Bonacorsi, S. P., M. R. Scavizzi, A. Guiyoule, J. H. Amouroux, and E. Carniel. 1994. Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection. Antimicrob. Agents Chemother. 38:481-486.
6. Boulanger, L. L., P. Ettestad, J. D. Fogarty, D. T. Dennis, D. Romig, and G. Mertz. 2004. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in New Mexico, 1985-1999. Clin. Infect. Dis. 38:663-669.
7. Brummett, R. E., and K. E. Fox. 1989. Aminoglycoside-induced hearing loss in humans. Antimicrob. Agents Chemother. 33:797-800.
8. Butler, T., and D. T. Dennis. 2005. Yersinia species, including plague, p. 2691-2701. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practices of infectious diseases, 6th ed. Elsevier Churchill Livingstone, Philadelphia, PA.
9. Byrne, W. R., S. L. Welkos, M. L. Pitt, K. J. Davis, R. P. Brueckner, J. W. Ezzell, G. O. Nelson, J. R. Vaccaro, L. C. Battersby, and A. M. Friedlander. 1998. Antibiotic treatment of experimental pneumonic plague in mice. Antimicrob. Agents Chemother. 42:675-681.
10. Centers for Disease Control and Prevention. 1996. Prevention of plague. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 45(RR-14):1-15.
11. Centers for Disease Control and Prevention. 1997. Fatal human plague. Morb. Mortal. Wkly. Rep. 278:380-382.
12. Cohen, R. J., and J. L. Stockard. 1967. Pneumonic plague in an untreated plague-vaccinated individual. JAMA 202:365-366.
13. Dennis, D., and F. Meier. 1997. Plague, p. 21-47. In C. R. Horsburgh and A. M. Nelson (ed.), Pathology of emerging infections. ASM Press, Washington, DC.
14. Deziel, M. R., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Basset, L. Miller, K. Bush, M. Kelly, and G. L. Drusano. 2005. Identification of effective antimicrobial regimens for use in humans for the therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
15. Drusano, G. L., J. A. Bilello, S. L. Preston, E. O'Mara, S. Kaul, S. Schnittman, and R. Echols. 2001. Hollow fiber unit evaluation of a new human immunodeficiency virus (HIV)-1 protease inhibitor, BMS 232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. 183:1126-1129.
16. Edberg, S. C. 1986. The measurement of antibiotics in human body fluids: techniques and significance, p. 382-399. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, MD.
17. Frean, J. A., L. Arntzen, T. Capper, A. Bryskier, and K. P. Klugman. 1996. In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus. Antimicrob. Agents Chemother. 40:2646-2647.
18. Galimand, M., A. Guiyoule, G. Gerbaud, B. Rasoamanana, S. Chanteau, E. Carniel, and P. Courvalin. 1997. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N. Engl. J. Med. 337:677-680.
19. Girard, G. 1955. Plague. Annu. Rev. Microbiol. 9:253-276.
20. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses Mycobacterium tuberculosis resistance using an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
21. Inglesby, T. V., D. T. Dennis, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, D. A. Fine, A. M. Friedlander, J. Hauer, J. F. Koerner, M. Layton, J. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, M. Schoch-Spana, and K. Tonat. 2000. Plague as a biological weapon: medical and public health management. JAMA 283: 2281-2290.
22. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
23. Jumbe, N. L., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in-vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
24. Kao, L. M., K. Bush, R. Barnewell, J. Estep, F. W. Thalacker, P. H. Olson, G. Drusano, N. Minton, S. Chien, A. Hemeryck, and M. F. Kelley. 2006. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob. Agents Chemother. 50:3535-3542.
25. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1990. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. 74:179-184.
26. McCrumb, F. R., Jr., A. Larson, and K. F. Meyer. 1953. The chemotherapy of experimental plague in the primate host. J. Infect. Dis. 92:273-287.
27. McCrumb, F. R., Jr., S. Mercier, J. Robic, M. Bouillat, J. E. Smadel, T. E. Woodward, and K. Goodner. 1953. Chloramphenicol and terramycin in the treatment of pneumonic plague. Am. J. Med. 14:284-293.
28. Medical Economics Company. 2000. Physicians' desk reference, p. 2157-2165. Medical Economics Company, Mantvale, NJ.
29. Mwengee, W., T. Butler, S. Mgema, G. Mhina, Y. Almasi, C. Bradley, J. B. Formanik, and C. G. Rochester. 2006. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin. Infect. Dis. 42:614-621.
30. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard; NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
31. Perry, R. D., and J. D. Fetherston. 1997. Yersinia pestis - etiologic agent of plague. Clin. Microbiol. Rev. 10:35-66.
32. Poland, J. D. 1983. Plague, p. 1227-1237. In P. D. Hoeprich (ed.), Infectious diseases: a modern treatise of infectious processes. Harper & Row, Philadelphia, PA.
33. Rasoamanana, B., P. Coulanges, P. Michel, and N. Rasolofonirina. 1989. Sensitivity of Yersinia pestis to antibiotics: 277 strains isolated in Madagascar between 1926 and 1989. Arch. Inst. Pasteur Madagascar 56:37-53.
34. Russell, P., S. M. Eley, D. L. Bell, R. J. Manchee, and R. W. Titball. 1996. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. J. Antimicrob. Chemother. 37:769-774.
35. Russell, P., S. M. Eley, M. Green, A. J. Stagg, R. R. Taylor, M. Nelson, R. J. Beedham, D. L. Bell, D. Rogers, D. Whittington, and R. W. Titball. 1998. Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. J. Antimicrob. Chemother. 41:301-305.
36. Slack, P. 1989. The black death past and present. 2. Some historical problems. Trans. R. Soc. Trop. Med. Hyg. 83:461-463.
37. Smith, M. D., D. X. Vinh, N. T. T. Hoa, J. Wain, D. Thung, and W. J. White. 1995. In vitro antimicrobial susceptibilities of strains of Yersinia pestis. Antimicrob. Agents Chemother. 39:2153-2154.
38. Traeger, M. S., S. T. Wiersma, N. E. Rosenstein, J. M. Malecki, C. W. Shepard, P. L. Raghunathan, S. P. Pillai, T. Popovic, C. P. Quinn, R. F. Meyer, S. R. Zaki, S. Kumar, S. M. Bruce, J. J. Sejvar, P. M. Dull, B. C. Tierney, J. D. Jones, and B. A. Perkins. 2002. First case of bioterrorism-related inhalational anthrax in the United States, Palm Beach County, Florida, 2001. Emerg. Infect. Dis. 8:1029-1034.
39. Werner, S. B., C. E. Weidmer, B. C. Nelson, G. S. Nygaard, R. M. Goethals, and J. D. Poland. 1984. Primary plague pneumonia contracted from a domestic cat at South Lake Tahoe, Calif. JAMA 251:929-931.
40. Wright, D. H., V. K. Herman, F. N. Konstantinides, and J. C. Rotschafer. 1998. Determination of quinolone antibiotics in growth media by reversed-phase high-performance liquid chromatography. J. Chromatogr. B 709:97-104.
41. Zhu, M., W. J. Burman, G. S. Jaresko, S. E. Berning, R. W. Jelliffe, and C. A. Peloquin. 2001. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 21:1037-1045.